FDA Approves Revolution Medicines’ Rasonque (daraxonrasib), an Oral Multi‑Selective RAS(ON) Inhibitor, for Metastatic Pancreatic Cancer
The U.S. Food and Drug Administration (FDA) has approved Revolution Medicines’ Rasonque (daraxonrasib) for the...
Revolution Medicines
BeOne Medicines and Revolution Medicines Announce Clinical Collaboration and Regional Licensing Deal on RAS(ON) Inhibitors Across Select Asian Markets
BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced a multifaceted collaboration agreement with...
Merck Abandons $32 Billion Revolution Medicines Acquisition Over Price Dispute
Merck & Co. Inc. (MSD, NYSE: MRK) has reportedly ended acquisition talks with Revolution Medicines after the...
EQRx Inc. to be Acquired by Revolution Medicines in All-Stock Transaction
US-based EQRx Inc. (NASDAQ: EQRX) has revealed that a definitive agreement has been signed for...